Navigation Links
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
Date:9/17/2010

SAN JOSE, Calif., Sept. 17 /PRNewswire/ -- Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept®, a leading medication for the treatment of Alzheimer's disease.

The company developed the weekly Aricept(r) patch based on a license agreement executed between Teikoku Pharma USA, Inc. and Eisai Co., Ltd. (Eisai) in February 2009. The acceptance of the NDA indicates that the FDA deems the company's submission to be sufficient to review. The NDA was submitted to the FDA by Teikoku Pharma USA, Inc. on June 30, 2010. If approved, Eisai's subsidiary, Eisai Inc., will hold marketing rights in the U.S.

The Aricept® transdermal patch formulation employs a unique drug delivery system, making it the world's first weekly transdermal patch for the treatment of Alzheimer's disease. It was developed to provide a potential new treatment option to Alzheimer's disease patients who have trouble swallowing, as well as to reduce the burden on caregivers and family members who administer medication to patients.

About Teikoku

Teikoku Pharma USA, Inc., a wholly-owned subsidiary of Teikoku Seiyaku Co., Ltd. that is a leading supplier of the topical analgesic transdermal patch, Lidoderm®, in the world, is a specialty pharmaceutical company that develops and manufactures enhanced pharmaceutical products with its transdermal drug delivery technology. Teikoku focuses its efforts on two therapeutic areas: chronic and acute pain, and the central nervous system (CNS). The company looks forward to exploring a new field of CNS with the systemic transdermal patch.  Teikoku is committed to applying its transdermal technology for the benefit of patients and partners. For more information, please visit www.teikokuusa.com.

About Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovered and developed Aricept® (Donepezil HCl tablets), the number-one prescribed Alzheimer's medication worldwide. It is sold in approximately 75 countries. In the United States, the product is co-promoted by Eisai Inc. and Pfizer Inc. and distributed by Eisai Inc. Aricept® continues to be studied for various potential new indications and formulations. Eisai focuses its efforts on three therapeutic areas: integrative neuroscience, integrative oncology, and vascular and immunology reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. For more information, please visit www.eisai.co.jp.


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
2. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
3. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
4. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
5. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
8. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
11. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 23, 2017 ... 2021, a latest research report. The global vagus nerve ... shift of surgeons focus toward minimally invasive VNS procedures. ... limited to few developed countries having high standards of ... ...
(Date:3/22/2017)... , 22 de marzo de 2017   ... líder de soluciones de productos y servicios para ... que ha adquirido EPL Archives, Inc., una organización ... clientes en todo el ciclo de vida de ... una muestra de archivo, almacenamiento de documentos y ...
(Date:3/22/2017)... , Mar. 22, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 10.9% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Medicine Technology:
(Date:3/22/2017)... Chesapeake, VA (PRWEB) , ... March 22, 2017 ... ... offering asset protection assistance and financial consultations to families and business owners in ... raise support for the local American Cancer Society Relay For Life event. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to communities across eastern Texas, is announcing a charity drive in ... to hungry children and adults. , Consistently a top-rated nonprofit organization for ...
(Date:3/22/2017)... ... , ... Schneider Insurance and Financial, a southern Montana firm providing asset protection ... is launching a charity event aimed at raising local support for Zoo Montana. , ... and is home to a broad variety of animals from all over the world. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Chris Humphrey Insurance Agency, a North Carolina ... throughout the coastal plains region, is initiating a charity event to raise support for ... first diagnosed with leukemia on a Friday evening in September 2014. At the time, ...
(Date:3/22/2017)... ... March 22, 2017 , ... College basketball surges to its peak during ... recruiting – that is, recruiting people to be foster parents. Through a televised spot, ... are in foster care due to abuse, neglect and other family challenges. People who ...
Breaking Medicine News(10 mins):